Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing-Reference-Cited by-同舟云学术

Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing

Published:2023-10 Issue: Volume:453 Page:120811
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Ihara Keiko,Ohtani Seiya,Watanabe Narumi,Takahashi Nobuyuki,Miyazaki Naoki,Takemura Ryo,Hori Satoko,Nakahara Jin,Takizawa Tsubasa

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference19 articles.

1. A controlled trial of erenumab for episodic migraine;Goadsby;N. Engl. J. Med.,2017

2. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial;Skljarevski;Cephalalgia,2018

3. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial;Dodick;JAMA,2018

4. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial;Sakai;Cephalalgia. Rep.,2020

5. Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients;Sakai;Headache,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching of monoclonal antibodies against the calcitonin gene-related peptide or its receptor in migraine. Results from a Spanish Cohort;Neurology Perspectives;2024-10

2. Switching CGRP(r) MoAbs in migraine: what evidence?;Expert Opinion on Biological Therapy;2024-05-03

3. Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine;Journal of Clinical Neurology;2024

4. Response to letter: “Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule” by Suzuki et al.;Journal of the Neurological Sciences;2023-12

5. Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule;Journal of the Neurological Sciences;2023-12